Skip to content
Screener

Nuvation Bio NUVB Total Liabilities & Equity

Total Liabilities & Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$87.63B-7.4%
Pfizer logo
PfizerPFE
$207.62B-0.2%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$504.61M+187%
Immunome logo
ImmunomeIMNM
$619.79M+80.9%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$183.97M-24.2%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$349.3M+62.1%

Other financials

Income statement

See full
Revenue$31.7M+556%
Gross profit$9.8M+1,340%
Operating income-$51.0M+19.7%
Net income-$62.8M-6.5%
EPS (diluted)-$0.18-5.9%

Balance sheet

See full
Cash & equivalents$258.6M+4.3%
Total debt$9.5M-83.5%
Total equity$253.9M-31.9%
Total assets$744.5M+15.0%

Cash flow

See full
Operating cash flow-$43.0M+10.8%
CapEx$254.0K+40.3%
Free cash flow-$43.2M+10.6%

Valuation

See full
Market cap$2.15B+168%
Enterprise value$1.9B+211%
P/S12.6×-43.1×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-81%-39.4pp
Net margin-88.2%-42.7pp
FCF margin-75.7%-36.6pp

Returns & leverage

See full
Return on equity-47.8%-9.8pp
Debt / equity-0.1×
Current ratio8.4×-1.0×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Nuvation Bio’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:55 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336646
Line itemJune 30, 2026December 31, 2025
Total liabilities490,639289,106
Commitments and contingencies (Note 10)
Stockholders’ equity
Class A and Class B common stock and additional paid in capital, $0.0001 par value per share; 1,060,000,000 (Class A 1,000,000,000, Class B 60,000,000) shares authorized as of June 30, 2026 and December 31, 2025 respectively, 349,822,479 (Class A 348,822,479, Class B 1,000,000) and 346,503,675 (Class A 345,503,675, Class B 1,000,000) shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively1,429,2881,421,273
Accumulated deficit(1,172,813)(1,115,370)
Accumulated other comprehensive loss(2,611)(187)
Total stockholders’ equity253,864305,716
Total liabilities and stockholders’ equity$744,503$594,822

Item 1. Financial Statements.

FAQ

What is Nuvation Bio's total liabilities & equity?
Nuvation Bio (NUVB) reported total liabilities & equity of $744.5M in Q2 2026.
How has Nuvation Bio's total liabilities & equity changed year-over-year?
Nuvation Bio's total liabilities & equity increased by 15.0% year-over-year, from $647.23M to $744.5M.
What is the long-term trend for Nuvation Bio's total liabilities & equity?
Over 5 years (2020 to 2025), Nuvation Bio's total liabilities & equity has grown at a 21.8% compound annual growth rate (CAGR), from $221.79M to $594.82M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Nuvation Bio's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude